MEP34208A - Hapten-carrier conjugates for treating and preventing nicotine addiction - Google Patents

Hapten-carrier conjugates for treating and preventing nicotine addiction

Info

Publication number
MEP34208A
MEP34208A MEP-342/08A MEP34208A MEP34208A ME P34208 A MEP34208 A ME P34208A ME P34208 A MEP34208 A ME P34208A ME P34208 A MEP34208 A ME P34208A
Authority
ME
Montenegro
Prior art keywords
hapten
nicotine
conjugates
treating
carrier
Prior art date
Application number
MEP-342/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Sofiane Ennifar
Ali Ibrahim Fattom
Robert B Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP34208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of MEP34208A publication Critical patent/MEP34208A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0013Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/816Alkaloids, amphetamines, and barbiturates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-342/08A 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction MEP34208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction
PCT/US1999/028272 WO2000032239A1 (en) 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Publications (1)

Publication Number Publication Date
MEP34208A true MEP34208A (en) 2011-02-10

Family

ID=22747358

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-342/08A MEP34208A (en) 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Country Status (26)

Country Link
US (7) US6232082B1 (de)
EP (3) EP1135166B9 (de)
JP (2) JP4971542B2 (de)
KR (1) KR100656836B1 (de)
CN (2) CN100586481C (de)
AT (1) ATE279211T1 (de)
AU (1) AU763001B2 (de)
BR (1) BR9915852A (de)
CA (1) CA2352765C (de)
DE (1) DE69921178T2 (de)
DK (1) DK1135166T3 (de)
EA (1) EA004956B1 (de)
ES (1) ES2229800T3 (de)
HK (3) HK1042428B (de)
HU (1) HUP0104365A3 (de)
IL (2) IL143474A0 (de)
ME (1) MEP34208A (de)
MX (1) MXPA01005511A (de)
NO (1) NO331998B1 (de)
NZ (1) NZ512103A (de)
PL (1) PL199253B1 (de)
PT (1) PT1135166E (de)
RS (1) RS51273B (de)
TR (1) TR200102411T2 (de)
WO (1) WO2000032239A1 (de)
ZA (1) ZA200104477B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2002058635A2 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
WO2003082329A2 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
IL165249A0 (en) 2002-07-18 2005-12-18 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
ES2285233T3 (es) * 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006091796A2 (en) * 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2007064478A2 (en) * 2005-11-28 2007-06-07 Nabi Biopharmaceuticals Method for making nicotine hapten
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007100755A1 (en) * 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP1849780A1 (de) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Impfstoff gegen Nikotinsucht
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
JP5630998B2 (ja) * 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP3424525A1 (de) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Impfstoffnanotechnologie
EP2065398A1 (de) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Humane, monoklonale, nikotinspezifische Antikörper
CN101878228A (zh) * 2007-11-29 2010-11-03 赛托斯生物技术公司 尼古丁特异性人单克隆抗体
CN102056624A (zh) * 2008-06-04 2011-05-11 康奈尔大学 用于防治成瘾的疫苗
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US8232072B2 (en) * 2008-06-13 2012-07-31 Nabi Biopharmaceuticals Smoking cessation kit and method
ES2396169T3 (es) * 2008-08-08 2013-02-19 Novartis Ag Proceso para la preparación de haptenos basados en nicotina
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
JP5016733B2 (ja) 2008-12-09 2012-09-05 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫賦活性オリゴヌクレオチド
WO2011014679A1 (en) 2009-07-31 2011-02-03 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
WO2011031298A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
EP2477974A2 (de) * 2009-09-14 2012-07-25 The Scripps Research Institute Nikotinhaptene, immunkonjugate damit und ihre verwendungen
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
CN102892429B (zh) 2010-03-17 2016-08-31 康奈尔大学 基于被破坏的腺病毒的抗滥用药物疫苗
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
WO2012099717A1 (en) * 2011-01-04 2012-07-26 National Jewish Health Leukotrienes and asthma exacerbation risk
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
CN106458971A (zh) * 2014-05-19 2017-02-22 斯克利普斯研究院 用于尼古丁疫苗开发的光学纯半抗原
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
AU2018283973A1 (en) 2017-06-11 2020-01-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR20200089255A (ko) 2017-08-15 2020-07-24 블링크 바이오메디컬 에스아에스 신규 니코틴-결합 항체
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US11333372B2 (en) 2018-03-09 2022-05-17 Scot Matthew Duncan Energy recovery high efficiency dehumidification system
US20220267474A1 (en) * 2018-06-06 2022-08-25 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
EP0194158A3 (de) 1985-03-08 1988-02-24 Baylor College of Medicine Anti-Nikotin- und Anti-Kotinin-Antikörper (monoklonale und andere) und deren Verwendungen in Nikotin- und Kotinin-Testverfahren
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
DE3884731D1 (de) 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (de) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoklonaler Antikörper gegen Morphin, Bereitung von monoklonalen Antikörpern, Testsatz und Verfahren zur Bestimmung von Morphin
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (de) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
EP0613899B1 (de) 1993-03-04 2003-01-15 Matsushita Electric Industrial Co., Ltd. Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
JP4179422B2 (ja) 1994-04-08 2008-11-12 メルク パテント ゲーエムベーハー スギ花粉アレルギーを治療するための医薬組成物
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996030049A2 (en) 1995-03-31 1996-10-03 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US6455047B1 (en) * 1997-09-19 2002-09-24 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
EA200100610A1 (ru) 2002-04-25
US20080026000A1 (en) 2008-01-31
PT1135166E (pt) 2005-01-31
JP2002531421A (ja) 2002-09-24
HK1091415A1 (en) 2007-01-19
IL143474A (en) 2006-06-11
EP2324855A1 (de) 2011-05-25
US6773891B2 (en) 2004-08-10
ZA200104477B (en) 2002-01-16
US6518031B2 (en) 2003-02-11
CA2352765C (en) 2011-02-15
US6232082B1 (en) 2001-05-15
US20030165950A1 (en) 2003-09-04
DK1135166T3 (da) 2005-02-14
EP1135166B1 (de) 2004-10-13
US20110002957A1 (en) 2011-01-06
HK1043061B (zh) 2006-07-07
HK1042428A1 (en) 2002-08-16
EP1135166B9 (de) 2005-02-02
US8026109B2 (en) 2011-09-27
CN1329508A (zh) 2002-01-02
AU763001B2 (en) 2003-07-10
RS51273B (sr) 2010-12-31
CN1220521C (zh) 2005-09-28
HK1042428B (zh) 2005-07-29
NO20012589D0 (no) 2001-05-25
JP4971542B2 (ja) 2012-07-11
US20110217320A1 (en) 2011-09-08
NO331998B1 (no) 2012-05-21
CN1768861A (zh) 2006-05-10
DE69921178D1 (de) 2004-11-18
US20050136047A1 (en) 2005-06-23
KR20010090854A (ko) 2001-10-19
JP2011079849A (ja) 2011-04-21
US7776620B2 (en) 2010-08-17
EP1135166A1 (de) 2001-09-26
YU39601A (sh) 2003-10-31
IL143474A0 (en) 2002-04-21
ES2229800T3 (es) 2005-04-16
WO2000032239A9 (en) 2002-08-22
CN100586481C (zh) 2010-02-03
PL349012A1 (en) 2002-06-17
EA004956B1 (ru) 2004-10-28
US7247502B2 (en) 2007-07-24
WO2000032239A1 (en) 2000-06-08
ATE279211T1 (de) 2004-10-15
KR100656836B1 (ko) 2006-12-12
CA2352765A1 (en) 2000-06-08
DE69921178T2 (de) 2005-11-17
US20020004208A1 (en) 2002-01-10
HUP0104365A3 (en) 2002-05-28
PL199253B1 (pl) 2008-08-29
HUP0104365A2 (hu) 2002-04-29
NO20012589L (no) 2001-07-20
AU2033500A (en) 2000-06-19
TR200102411T2 (tr) 2002-01-21
BR9915852A (pt) 2004-06-29
HK1043061A1 (en) 2002-09-06
EP1512414A1 (de) 2005-03-09
NZ512103A (en) 2003-09-26
MXPA01005511A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
MEP34208A (en) Hapten-carrier conjugates for treating and preventing nicotine addiction
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
DK0651646T3 (da) Terapeutiske konjugater af toksiner og lægemidler
BR9711580A (pt) Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BR0312297A (pt) Conjugados veìculos de hapteno e seu uso
AR048098A1 (es) Conjugados de caliqueamicina
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DK1507554T3 (da) Lactoferrin i behandlingen af maligne neoplasmer og andre hyperproliferative sygdomme
DK0814843T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
IS2259B (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
WO2005042028A3 (en) Il-13 conjugated to an immunogen and uses thereof
AU2001239180A1 (en) Immunomodulatory effective compositions, methods for the production thereof and their use
Arjen De Vos et al. Results of a phase 1 safety and immunogenicity trial with NicVAX, a conjugated nicotine vaccine